NCT02213107View on ClinicalTrials.gov

Enzalutamide & Dutasteride/Finasteride as 1st Line Treatment for Patients =/> 65 Years Old With Prostate Cancer.

PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

October 31, 2023

Study Completion Date

October 31, 2023

Conditions
Prostate Cancer
Interventions
DRUG

Enzalutamide and Dutasteride or finasteride

"Use of either two oral drugs together~1. Enzalutamide by mouth daily and dutasteride by mouth daily or~2. Enzalutamide by mouth daily and finasteride by mouth daily"

Trial Locations (2)

14642

University of Rochester, Rochester

53226

Medical College of Wisconscin, Milwaukee

All Listed Sponsors
lead

University of Rochester

OTHER

NCT02213107 - Enzalutamide & Dutasteride/Finasteride as 1st Line Treatment for Patients =/> 65 Years Old With Prostate Cancer. | Biotech Hunter | Biotech Hunter